Drug Trial Radar · NCT06418061
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Jan 8, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.
Conditions
- Unresectable
- Locally Advanced or Metastatic Solid Tumors
Interventions
IBI3005Drug
Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of subjects with adverse eventsTime frame: Up to 3 years
- Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 3 years
- Number of subjects with clinically significant changes in vital signsTime frame: Up to 3 years
- Dose limiting toxicities (DLTs)Time frame: Up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Cancer Hospital & Institute
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.